Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces final results from Phase 3 REALIZE study against HCV

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Watson, GeneraMedix receive FDA approval for Nulecit to treat iron deficiency anemia

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Alnylam completes patient enrollment in ALN-VSP Phase I trial against liver cancer

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Study finds frequent anaemia in patients with chronic respiratory failure

Study finds frequent anaemia in patients with chronic respiratory failure

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

Uterine fibroid embolization reduces fibroid-related urinary symptoms

Uterine fibroid embolization reduces fibroid-related urinary symptoms

Prostate cancer updates

Prostate cancer updates

Inflammatory bowel disease in children - Delays in diagnosis common

Inflammatory bowel disease in children - Delays in diagnosis common

CBAI partners with BlueCross and offers cord blood banking services to their members

CBAI partners with BlueCross and offers cord blood banking services to their members

BMY receives FDA approval for YERVOY to treat metastatic melanoma

BMY receives FDA approval for YERVOY to treat metastatic melanoma

XTL announces MinoGuard acquisition

XTL announces MinoGuard acquisition

Inadequate nutrition linked to greater risk of anemia in postmenopausal women

Inadequate nutrition linked to greater risk of anemia in postmenopausal women

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

Affymax, Takeda's peginesatide Phase 3 data in dialysis patient to be presented at NKF meeting

New insights into cancer genome may lead to designer drugs for myeloma

New insights into cancer genome may lead to designer drugs for myeloma

Xenon founder receives Canada Wightman Award for leadership in medical science

Xenon founder receives Canada Wightman Award for leadership in medical science

Iron deficiency during pregnancy may impact child's brain development

Iron deficiency during pregnancy may impact child's brain development

Oncologists to discuss treatment of blood cancer in elderly

Oncologists to discuss treatment of blood cancer in elderly

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.